Endovascular treatment plus anticoagulation for severe CVST in the MENA region

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

REVIVE-CVST is a multicenter, randomized trial comparing endovascular thrombectomy plus anticoagulation versus anticoagulation alone in adults with severe CVST. Participants are enrolled within 21 days of symptom onset and randomized 1:1, stratified by site and intracerebral hemorrhage status. The intervention uses mechanical thrombectomy, aspiration, or balloon-assisted approaches within 24 hours of randomization, in addition to standard anticoagulation. Follow-up visits occur at 30, 90, and 180 days, with the primary endpoint assessed at 180 days using the modified Rankin Scale across its full range. The study aims to enroll about 440 participants at roughly 15 centers in the MENA region.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age 18-65 years, inclusive
* Radiologically confirmed cerebral venous sinus thrombosis (CVST) by CT venography (CTV), MR venography (MRV), or digital subtraction angiography (DSA), with thrombosis of at least one major dural sinus
* Acute or subacute presentation with symptom onset within 21 days of randomization
* MRI phase characterization confirming acute or subacute phase
* At least one risk factor for poor outcome: symptoms of intracranial hypertension (severe headache, papilledema, visual obscurations), focal neurological deficit, seizures, altered consciousness (GCS 9-14), intracranial hemorrhage from venous congestion, or deep venous system thrombosis
* Significant venous outflow obstruction on imaging
* Written informed consent from patient or legally authorized representative

Exclusion Criteria:

* Isolated cortical vein thrombosis without dural sinus involvement
* Isolated cavernous sinus thrombosis
* Chronic-phase CVST on MRI phase characterization
* Pre-morbid modified Rankin Scale (mRS) score greater than 2
* Glasgow Coma Scale (GCS) score less than 9 at randomization
* Imminent risk of transtentorial herniation requiring emergent decompressive craniectomy
* Massive cerebral edema with midline shift greater than 10 mm requiring surgical intervention
* Active systemic bleeding or hemorrhagic diathesis
* Severe allergy to iodinated contrast media
* CVST secondary to active hematological malignancy or life expectancy less than 12 months
* Pregnancy
* Participation in another interventional clinical trial within 30 days
* Any condition rendering the patient unsuitable for study participation per investigator judgment

Where it's running

• Alexandria University, Smouha Comprehensive Stroke Center
  Alexandria, Egypt Recruiting
• Ain Shams University
  Cairo, Egypt Recruiting
• Cairo University
  Cairo, Egypt Recruiting
• Neurology Department, Al-Azhar University
  Cairo, Egypt Recruiting
• King Khalid University
  Abhā, Saudi Arabia Recruiting
• King Abdullah Medical City
  Mecca, Saudi Arabia Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Danang Cerebral Venous Thrombosis Registry

  This registry collects information on adults with cerebral venous thrombosis admitted to Danang Hospital to see how the condition presents, what imaging shows, risk factors, and how patients recover.

  Recruiting Da Nang Hospital · Da Nang, Da Nang · NCT07890675

• Investigating cerebral vein thrombosis in Norway

  This study looks at how common cerebral vein thrombosis is in Norway, what causes it, how it's treated, and what happens to patients in the long run.

  Recruiting University Hospital, Akershus · Lørenskog · NCT05021198

• Cerebral Venous Thrombosis Cohort: Features and Treatments in China

  This study follows people with cerebral venous thrombosis in China to see how the condition presents, progresses, and responds to current treatments, while collecting blood and spinal fluid to explore biomarkers.

  Recruiting Capital Medical University · Beijing · NCT03919305

• Anticoagulation Plus Tocilizumab for Acute Cerebral Venous Thrombosis

  This study tests whether adding a single dose of tocilizumab to standard blood thinners helps people with acute cerebral venous thrombosis.

  Recruiting Capital Medical University · Beijing, Beijing Municipality · NCT07801638

• Anticoagulation plus batroxobin for acute cerebral venous thrombosis

  This trial tests whether adding batroxobin to standard anticoagulation helps adults with acute cerebral venous thrombosis.

  Recruiting Phase 4 Xuanwu Hospital, Beijing · Beijing, Beijing Municipality · NCT07352358

• DOAC treatment outcomes for cerebral venous thrombosis in Vietnam

  This project will try direct oral anticoagulants (dabigatran or rivaroxaban) in adults with cerebral venous thrombosis to see if they are safe and effective in routine care.

  Recruiting Bach Mai Hospital · Hanoi, Hanoi · NCT07083609

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.